{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T16:34:01Z","timestamp":1792254841107,"version":"4.4.0"},"reference-count":149,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ard.2025.02.021","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T23:27:02Z","timestamp":1744759622000},"page":"1561-1590","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Antirheumatic drugs in reproduction, pregnancy, and lactation: a systematic literature review informing the 2024 update of the EULAR recommendations"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2541-5766","authenticated-orcid":false,"given":"Andrea","family":"Pluma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2721-1249","authenticated-orcid":false,"given":"Sabrina","family":"Hamroun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1943-9834","authenticated-orcid":false,"given":"Linda","family":"R\u00fcegg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1858-5452","authenticated-orcid":false,"given":"Irene","family":"Cecchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1535-3241","authenticated-orcid":false,"given":"Malte","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8958-9493","authenticated-orcid":false,"given":"Luis Fernando","family":"Perez-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Rivero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1210-4347","authenticated-orcid":false,"given":"Axel","family":"Finckh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0147-4112","authenticated-orcid":false,"given":"Yvette","family":"Meissner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1134-993X","authenticated-orcid":false,"given":"Frauke","family":"F\u00f6rger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ard.2025.02.021_bib0001","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002752","article-title":"Fetal and maternal morbidity in pregnant patients with Lupus: a 10-year US nationwide analysis","volume":"9","author":"Mehta","year":"2023","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.ard.2025.02.021_bib0002","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/RHU.0000000000001935","article-title":"Pregnancy outcomes in women with rheumatoid arthritis: a systematic review and meta-analysis","volume":"29","author":"Sim","year":"2023","journal-title":"J Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.ard.2025.02.021_bib0003","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/S2665-9913(23)00001-2","article-title":"Temporal trends in adverse pregnancy outcomes in axial spondyloarthritis in Sweden: a cohort study","volume":"5","author":"Morin","year":"2023","journal-title":"Lancet Rheumatol"},{"issue":"5","key":"10.1016\/j.ard.2025.02.021_bib0004","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","article-title":"The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation","volume":"75","author":"Gotestam Skorpen","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.02.021_bib0005","unstructured":"EULAR SOPs\u2014Standard Operating Procedures for Task Forces 2024, Version 52 [Internet]. [Accessed 2024 Oct 31). Available from:https:\/\/www.eular.org\/web\/static\/lib\/pdfjs\/web\/viewer.html?file=https:\/\/www.eular.org\/document\/download\/680\/b9eb08d0-faca-4606-8ed9-d0539b3f312a\/660"},{"key":"10.1016\/j.ard.2025.02.021_bib0006","article-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.4 [Internet]","author":"Higgins","year":"2023","journal-title":"Cochrane"},{"key":"10.1016\/j.ard.2025.02.021_bib0007","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.ard.2025.02.021_bib0008","doi-asserted-by":"crossref","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.ard.2025.02.021_bib0009","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.ard.2025.02.021_bib0010","series-title":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","year":"2014"},{"issue":"10","key":"10.1016\/j.ard.2025.02.021_bib0011","first-page":"2127","article-title":"Methodological quality of case series studies: an introduction to the JBI critical appraisal tool","volume":"18","author":"Munn","year":"2020","journal-title":"JBI Evid Synth"},{"key":"10.1016\/j.ard.2025.02.021_bib0012","unstructured":"Oxford Centre for Evidence-Based Medicine: Levels of Evidence (March 2009) [Internet]. 2009. Available from:https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/oxford-centre-for-evidence-basedmedicine-levels-of-evidence-march-2009.2009"},{"issue":"9","key":"10.1016\/j.ard.2025.02.021_bib0013","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1136\/gutjnl-2021-325317","volume":"71","author":"Odufalu","year":"2022","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.ard.2025.02.021_bib0014","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12916-023-02817-7","article-title":"Adverse birth outcomes and early-life infections after in utero exposure to corticosteroids for inflammatory bowel disease: a Danish nationwide cohort study","volume":"21","author":"J\u00f8lving","year":"2023","journal-title":"BMC Med"},{"key":"10.1016\/j.ard.2025.02.021_bib0015","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.reprotox.2018.05.003","article-title":"No evidence of adverse pregnancy outcome after exposure to ibuprofen in the first trimester\u2014evaluation of the national Embryotox cohort","volume":"79","author":"Dathe","year":"2018","journal-title":"Reprod Toxicol"},{"key":"10.1016\/j.ard.2025.02.021_bib0016","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.reprotox.2018.02.007","article-title":"Safety of diclofenac use during early pregnancy: a prospective observational cohort study","volume":"77","author":"Padberg","year":"2018","journal-title":"Reprod Toxicol"},{"issue":"8","key":"10.1016\/j.ard.2025.02.021_bib0017","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1111\/1471-0528.12192","article-title":"Effects of ibuprofen, diclofenac, naproxen, and piroxicam on the course of pregnancy and pregnancy outcome: a prospective cohort study","volume":"120","author":"Nezvalov\u00e1-Henriksen","year":"2013","journal-title":"BJOG"},{"issue":"3","key":"10.1016\/j.ard.2025.02.021_bib0018","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.reprotox.2010.04.010","article-title":"First trimester diclofenac exposure and pregnancy outcome","volume":"30","author":"Cassina","year":"2010","journal-title":"Reprod Toxicol"},{"issue":"4","key":"10.1016\/j.ard.2025.02.021_bib0019","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00228-017-2385-1","article-title":"Exposure to cox-2 inhibitors (coxibs) during the first trimester and pregnancy outcome: a prospective observational cohort study","volume":"74","author":"Dathe","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.ard.2025.02.021_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2020.09.007","article-title":"Hydroxychloroquine early in pregnancy and risk of birth defects","volume":"224","author":"Huybrechts","year":"2021","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.ard.2025.02.021_bib0021","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/art.42015","article-title":"Birth outcomes in women who have taken hydroxycholoroquine during pregnancy: a prospective cohort study","volume":"74","author":"Chambers","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.ard.2025.02.021_bib0022","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1111\/j.1572-0241.2007.01216.x","article-title":"Therapeutic drug use in women with Crohn's disease and birth outcomes: a Danish nationwide cohort study","volume":"102","author":"N\u00f8rg\u00e5rd","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.ard.2025.02.021_bib0023","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.crohns.2011.01.009","article-title":"The effects of azathioprine on birth outcomes in women with inflammatory bowel disease (IBD)","volume":"5","author":"Shim","year":"2011","journal-title":"J Crohns Colitis"},{"issue":"4","key":"10.1016\/j.ard.2025.02.021_bib0024","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1053\/j.gastro.2020.11.038","article-title":"Pregnancy and neonatal outcomes after fetal exposure to biologics and thiopurines among women with inflammatory bowel disease","volume":"160","author":"Mahadevan","year":"2021","journal-title":"Gastroenterology"},{"issue":"14","key":"10.1016\/j.ard.2025.02.021_bib0025","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1177\/0961203310378669","article-title":"Pregnancy outcome in 396 pregnancies in patients with SLE in Saudi Arabia","volume":"19","author":"Al Arfaj","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.ard.2025.02.021_bib0026","first-page":"121","article-title":"Pregnancy with a favorable outcome in a patient with MCTD and pulmonary arterial hypertension treated with bosentan","volume":"24","author":"Aamer","year":"2021","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2025.02.021_bib0027","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s00296-019-04443-0","article-title":"Familial Mediterranean fever: assessment of clinical manifestations, pregnancy, genetic mutational analyses, and disease severity in a national cohort","volume":"40","author":"Bodur","year":"2020","journal-title":"Rheumatol Int"},{"issue":"6","key":"10.1016\/j.ard.2025.02.021_bib0028","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/aji.12514","article-title":"The efficacy and safety of cyclosporin A in pregnant patients with systemic autoimmune diseases","volume":"75","author":"Reggia","year":"2016","journal-title":"Am J Reprod Immunol"},{"issue":"7","key":"10.1016\/j.ard.2025.02.021_bib0029","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1002\/ibd.20858","article-title":"Cyclosporine treatment of steroid-refractory ulcerative colitis during pregnancy","volume":"15","author":"Branche","year":"2009","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"10.1016\/j.ard.2025.02.021_bib0030","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s00296-013-2765-5","article-title":"Adult-onset Still's disease and pregnancy: about ten cases and review of the literature","volume":"34","author":"Gerfaud-Valentin","year":"2014","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.ard.2025.02.021_bib0031","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.reprotox.2020.04.073","article-title":"Pregnancy outcomes in patients treated with leflunomide, the parent compound of the multiple sclerosis drug teriflunomide","volume":"95","author":"Henson","year":"2020","journal-title":"Reprod Toxicol"},{"issue":"7","key":"10.1016\/j.ard.2025.02.021_bib0032","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1177\/1352458519843055","article-title":"Pregnancy outcomes in patients with multiple sclerosis treated with teriflunomide: clinical study data and 5 years of post-marketing experience","volume":"26","author":"Vukusic","year":"2020","journal-title":"Mult Scler"},{"issue":"4","key":"10.1016\/j.ard.2025.02.021_bib0033","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1212\/CPJ.0000000000000717","article-title":"Teriflunomide-exposed pregnancies in a French cohort of patients with multiple sclerosis","volume":"10","author":"Barataud-Reilhac","year":"2020","journal-title":"Neurol Clin Pract"},{"key":"10.1016\/j.ard.2025.02.021_bib0034","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104184","article-title":"Fingolimod, teriflunomide and cladribine for the treatment of multiple sclerosis in women of childbearing age: description of drug utilization and exposed pregnancies in Germany","volume":"67","author":"Platzbecker","year":"2022","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"10.1016\/j.ard.2025.02.021_bib0035","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40120-014-0020-y","article-title":"Pregnancy outcomes following maternal and paternal exposure to teriflunomide during treatment for relapsing-remitting multiple sclerosis","volume":"3","author":"Kieseier","year":"2014","journal-title":"Neurol Ther"},{"issue":"5","key":"10.1016\/j.ard.2025.02.021_bib0036","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1002\/art.27358","article-title":"Birth outcomes in women who have taken leflunomide during pregnancy","volume":"62","author":"Chambers","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"28","key":"10.1016\/j.ard.2025.02.021_bib0037","article-title":"Twin pregnancy outcome following teriflunomide treatment in a relapsing-remitting multiple sclerosis patient: a case report","volume":"99","author":"D'Aleo","year":"2020","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"10.1016\/j.ard.2025.02.021_bib0038","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1136\/annrheumdis-2017-212078","article-title":"Leflunomide use during pregnancy and the risk of adverse pregnancy outcomes","volume":"77","author":"B\u00e9rard","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.02.021_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103529","article-title":"Pregnancy outcomes following maternal or paternal exposure to teriflunomide in the Danish MS population","volume":"59","author":"Andersen","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.ard.2025.02.021_bib0040","first-page":"2706","article-title":"Pregnancy outcomes in men and women treated with teriflunomide","volume":"9","author":"Andersen","year":"2018","journal-title":"a population-based Nationwide Danish Register Study. Front Immunol."},{"issue":"2","key":"10.1016\/j.ard.2025.02.021_bib0041","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002412","article-title":"Impact of rheumatoid arthritis and methotrexate on pregnancy outcomes: retrospective cohort study of the Italian Society for Rheumatology","volume":"8","author":"Zanetti","year":"2022","journal-title":"RMD Open"},{"issue":"5","key":"10.1016\/j.ard.2025.02.021_bib0042","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000024553","article-title":"Predicting factors of adverse pregnancy outcomes in Thai patients with systemic lupus erythematosus: a STROBE-compliant study","volume":"100","author":"Louthrenoo","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"10.1016\/j.ard.2025.02.021_bib0043","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1111\/1471-0528.17163","article-title":"Phosphodiesterase-5 inhibitors in pregnancy: systematic review and meta-analysis of maternal and perinatal safety and clinical outcomes","volume":"129","author":"Turner","year":"2022","journal-title":"BJOG"},{"issue":"7","key":"10.1016\/j.ard.2025.02.021_bib0044","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0219732","article-title":"The effects of sildenafil in maternal and fetal outcomes in pregnancy: a systematic review and meta-analysis","volume":"14","author":"Ferreira","year":"2019","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ard.2025.02.021_bib0045","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000453062","article-title":"Sildenafil in pregnancy: a systematic review of maternal tolerance and obstetric and perinatal outcomes","volume":"41","author":"Dunn","year":"2017","journal-title":"Fetal Diagn Ther"},{"issue":"9","key":"10.1016\/j.ard.2025.02.021_bib0046","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/apt.17189","article-title":"The safety of paternal and maternal use of 5-aminosalicylic acid during conception and pregnancy: a nationwide cohort study","volume":"56","author":"N\u00f8rg\u00e5rd","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.ard.2025.02.021_bib0047","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1177\/0961203318770536","article-title":"The efficacy of adjunct tacrolimus treatment in pregnancy outcomes in patients with systemic lupus erythematosus","volume":"27","author":"Ichinose","year":"2018","journal-title":"Lupus"},{"issue":"12","key":"10.1016\/j.ard.2025.02.021_bib0048","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1093\/ibd\/izy160","article-title":"Outcomes of pregnancies with maternal\/paternal exposure in the tofacitinib safety databases for ulcerative colitis","volume":"24","author":"Mahadevan","year":"2018","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"10.1016\/j.ard.2025.02.021_bib0049","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0223603","article-title":"Birth outcomes in women who have taken adalimumab in pregnancy: a prospective cohort study","volume":"14","author":"Chambers","year":"2019","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.ard.2025.02.021_bib0050","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/pds.4261","article-title":"Pregnancy and infant outcomes including major congenital malformations among women with chronic inflammatory arthritis or psoriasis, with and without etanercept use","volume":"26","author":"Carman","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.ard.2025.02.021_bib0051","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X221087650","article-title":"Pharmacovigilance pregnancy data in a large population of patients with chronic inflammatory disease exposed to certolizumab pegol","volume":"14","author":"Clowse","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"3","key":"10.1016\/j.ard.2025.02.021_bib0052","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/ajg.2017.501","article-title":"Long-term safety of in utero exposure to anti-TNF\u03b1 drugs for the treatment of inflammatory bowel disease: results from the multicenter European TEDDY study","volume":"113","author":"Chaparro","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.ard.2025.02.021_bib0053","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cgh.2017.08.041","article-title":"Use of biologic therapy by pregnant women with inflammatory bowel disease does not affect infant response to vaccines","volume":"16","author":"Beaulieu","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.ard.2025.02.021_bib0054","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood-2010-07-295444","article-title":"Pregnancy outcomes after maternal exposure to rituximab","volume":"117","author":"Chakravarty","year":"2011","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.ard.2025.02.021_bib0055","first-page":"2127","article-title":"Preterm deliveries in women with systemic lupus erythematosus","volume":"30","author":"Clark","year":"2003","journal-title":"J Rheumatol"},{"issue":"suppl 9","key":"10.1016\/j.ard.2025.02.021_bib0056","article-title":"Maternal and infant outcomes following abatacept exposure during pregnancy [abstract]","volume":"75","author":"Caesar","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.ard.2025.02.021_bib0057","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1111\/apt.17224","article-title":"Ustekinumab during pregnancy in patients with inflammatory bowel disease: a prospective multicentre cohort study","volume":"56","author":"Avni-Biron","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.ard.2025.02.021_bib0058","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.semarthrit.2016.05.004","article-title":"Tocilizumab use in pregnancy: analysis of a global safety database including data from clinical trials and post-marketing data","volume":"46","author":"Hoeltzenbein","year":"2016","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.ard.2025.02.021_bib0059","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2169\/internalmedicine.9607-22","article-title":"A woman with rheumatoid arthritis who successfully delivered a healthy child with continuous administration of sarilumab throughout pregnancy","volume":"62","author":"Mizutani","year":"2023","journal-title":"Intern Med"},{"issue":"5","key":"10.1016\/j.ard.2025.02.021_bib0060","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1111\/bjd.16901","article-title":"Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database","volume":"179","author":"Warren","year":"2018","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.ard.2025.02.021_bib0061","doi-asserted-by":"crossref","first-page":"e453","DOI":"10.1212\/NXI.0000000000000453","article-title":"Rituximab before and during pregnancy: a systematic review, and a case series in MS and NMOSD","volume":"5","author":"Das","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"5","key":"10.1016\/j.ard.2025.02.021_bib0062","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.semarthrit.2021.06.005","article-title":"Pregnancy outcomes in patients treated with belimumab: report from real-world experience","volume":"51","author":"Kao","year":"2021","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.ard.2025.02.021_bib0063","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/ibd\/izy294","article-title":"Safety of anti-TNF-alpha therapy during pregnancy on long-term outcome of exposed children: a controlled, multicenter observation","volume":"25","author":"Duricova","year":"2019","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"10.1016\/j.ard.2025.02.021_bib0064","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1093\/ecco-jcc\/jjy053","article-title":"Hepatitis B vaccination effective in children exposed to anti-tumour necrosis factor alpha in utero","volume":"12","author":"de Lima","year":"2018","journal-title":"J Crohns Colitis"},{"issue":"1","key":"10.1016\/j.ard.2025.02.021_bib0065","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2021-056021","article-title":"Safety of live-attenuated vaccines in children exposed to biologic response modifiers in utero","volume":"150","author":"Zerbo","year":"2022","journal-title":"Pediatrics"},{"issue":"Supplement_1","key":"10.1016\/j.ard.2025.02.021_bib0066","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjac190.0874","article-title":"P744 Safety of live vaccines in children exposed to biological agents for inflammatory bowel disease (IBD) in utero or during breastfeeding","volume":"17","author":"Chaparro","year":"2023","journal-title":"J Crohns Colitis"},{"issue":"9","key":"10.1016\/j.ard.2025.02.021_bib0067","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/S2352-4642(23)00136-0","article-title":"Immunological effects and safety of live rotavirus vaccination after antenatal exposure to immunomodulatory biologic agents: a prospective cohort study from the Canadian Immunization Research Network","volume":"7","author":"Fitzpatrick","year":"2023","journal-title":"Lancet Child Adolesc Health"},{"issue":"10","key":"10.1016\/j.ard.2025.02.021_bib0068","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1093\/rheumatology\/keac141","article-title":"A systematic review of live vaccine outcomes in infants exposed to biologic disease modifying anti-rheumatic drugs in utero","volume":"61","author":"Goulden","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.ard.2025.02.021_bib0069","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.crohns.2010.05.001","article-title":"Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease","volume":"4","author":"Cheent","year":"2010","journal-title":"J Crohns Colitis"},{"issue":"6","key":"10.1016\/j.ard.2025.02.021_bib0070","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.semarthrit.2021.09.004","article-title":"A systematic review of the safety of non-TNF inhibitor biologic and targeted synthetic drugs in rheumatic disease in pregnancy","volume":"51","author":"Nguyen","year":"2021","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.ard.2025.02.021_bib0071","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004183","article-title":"Neonatal and maternal adverse outcomes and exposure to nonsteroidal anti-inflammatory drugs during early pregnancy in South Korea: a nationwide cohort study","volume":"20","author":"Choi","year":"2023","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.ard.2025.02.021_bib0072","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1186\/s12884-022-04986-4","article-title":"Fetal adverse effects following NSAID or metamizole exposure in the 2nd and 3rd trimester: an evaluation of the German Embryotox cohort","volume":"22","author":"Dathe","year":"2022","journal-title":"BMC Pregnancy Childbirth"},{"issue":"10","key":"10.1016\/j.ard.2025.02.021_bib0073","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1136\/annrheumdis-2014-205383","article-title":"Fertility in women with rheumatoid arthritis: influence of disease activity and medication","volume":"74","author":"Brouwer","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2025.02.021_bib0074","first-page":"103","article-title":"Preconception use of pain-relievers and time-to-pregnancy: a prospective cohort study","volume":"32","author":"McInerney","year":"2017","journal-title":"Hum Reprod"},{"issue":"10","key":"10.1016\/j.ard.2025.02.021_bib0075","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1007\/s10067-018-4208-x","article-title":"Non-steroidal anti-inflammatory drug induces luteinized unruptured follicle syndrome in young female juvenile idiopathic arthritis patients","volume":"37","author":"Tomioka","year":"2018","journal-title":"Clin Rheumatol"},{"issue":"3","key":"10.1016\/j.ard.2025.02.021_bib0076","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1053\/j.gastro.2018.05.040","article-title":"Exposure concentrations of infants breastfed by women receiving biologic therapies for inflammatory bowel diseases and effects of breastfeeding on infections and development","volume":"155","author":"Matro","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ard.2025.02.021_bib0077","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.3389\/fimmu.2017.01123","article-title":"Immunological changes in blood of newborns exposed to anti-TNF-alpha during pregnancy","volume":"8","author":"Esteve-Sol\u00e9","year":"2017","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.ard.2025.02.021_bib0078","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1136\/annrheumdis-2017-211384","article-title":"Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study","volume":"76","author":"Clowse","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.ard.2025.02.021_bib0079","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/ecco-jcc\/jjy058","article-title":"Anti-TNF levels in cord blood at birth are associated with anti-TNF type","volume":"12","author":"Kanis","year":"2018","journal-title":"J Crohns Colitis"},{"issue":"1","key":"10.1016\/j.ard.2025.02.021_bib0080","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1111\/1346-8138.15124","article-title":"Serum infliximab level in an infant delivered from a mother with psoriatic arthritis receiving infliximab","volume":"47","author":"Takeuchi","year":"2020","journal-title":"J Dermatol"},{"issue":"9","key":"10.1016\/j.ard.2025.02.021_bib0081","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1136\/annrheumdis-2017-212366","article-title":"Minimal neonatal transfer of certolizumab pegol in a Japanese patient with rheumatoid arthritis","volume":"77","author":"Morita","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.ard.2025.02.021_bib0082","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jbspin.2015.07.004","article-title":"Certolizumab treatment during late pregnancy in patients with rheumatic diseases: low drug levels in cord blood but possible risk for maternal infections. A case series of 13 patients","volume":"83","author":"Forger","year":"2016","journal-title":"Joint Bone Spine"},{"issue":"9","key":"10.1016\/j.ard.2025.02.021_bib0083","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1093\/rheumatology\/kez135","article-title":"Abatacept concentrations in maternal serum and breast milk during breastfeeding and an infant safety assessment: a case study","volume":"58","author":"Saito","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.ard.2025.02.021_bib0084","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1093\/rheumatology\/kex305","article-title":"International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors","volume":"56","author":"Youngstein","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ard.2025.02.021_bib0085","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.reprotox.2019.05.029","article-title":"#20 Anakinra use during pregnancy and lactation: a case report","volume":"88","author":"Duman","year":"2019","journal-title":"Reprod Toxicol"},{"issue":"7","key":"10.1016\/j.ard.2025.02.021_bib0086","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1089\/bfm.2020.0068","article-title":"Belimumab concentrations in maternal serum and breast milk during breastfeeding and the safety assessment of the infant: a case study","volume":"15","author":"Saito","year":"2020","journal-title":"Breastfeed Med"},{"issue":"2","key":"10.1016\/j.ard.2025.02.021_bib0087","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s40744-021-00313-z","article-title":"Rituximab and canakinumab use during lactation: no detectable serum levels in breastfed infants","volume":"8","author":"Bosshard","year":"2021","journal-title":"Rheumatol Ther"},{"issue":"1","key":"10.1016\/j.ard.2025.02.021_bib0088","doi-asserted-by":"crossref","first-page":"e637","DOI":"10.1212\/NXI.0000000000000637","article-title":"Minimal breast milk transfer of rituximab, a monoclonal antibody used in neurological conditions","volume":"7","author":"Krysko","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"10.1016\/j.ard.2025.02.021_bib0089","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/jnnp-2022-329545","article-title":"Safety of breast feeding during rituximab treatment in multiple sclerosis","volume":"94","author":"R\u00f8d","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.ard.2025.02.021_bib0090","doi-asserted-by":"crossref","first-page":"e723","DOI":"10.1212\/NXI.0000000000000723","article-title":"Monoclonal antibody treatment during pregnancy and\/or lactation in women with MS or neuromyelitis optica spectrum disorder","volume":"7","author":"Ciplea","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"6","key":"10.1016\/j.ard.2025.02.021_bib0091","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/rheumatology\/kex039","article-title":"Low level of rituximab in human breast milk in a patient treated during lactation","volume":"56","author":"Bragnes","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.ard.2025.02.021_bib0092","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/rheumatology\/kez155","article-title":"Placental transfer of tocilizumab in a patient with rheumatoid arthritis","volume":"58","author":"Tada","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.ard.2025.02.021_bib0093","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1177\/1753495X20966094","article-title":"Tocilizumab drug levels during pregnancy and lactation: a woman who discontinued tocilizumab therapy until the end of the first trimester and resumed it after birth","volume":"14","author":"Saito","year":"2021","journal-title":"Obstet Med"},{"issue":"8","key":"10.1016\/j.ard.2025.02.021_bib0094","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1093\/rheumatology\/kez100","article-title":"Tocilizumab during pregnancy and lactation: drug levels in maternal serum, cord blood, breast milk and infant serum","volume":"58","author":"Saito","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.ard.2025.02.021_bib0095","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1093\/rheumatology\/key091","article-title":"Tocilizumab concentrations in maternal serum and breast milk during breastfeeding and a safety assessment in infants: a case study","volume":"57","author":"Saito","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.ard.2025.02.021_bib0096","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/ibd\/izaa325","article-title":"Detection of ustekinumab in breast milk of nursing mothers with Crohn disease","volume":"27","author":"Bar-Gil Shitrit","year":"2021","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"10.1016\/j.ard.2025.02.021_bib0097","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/ecco-jcc\/jjy153","article-title":"Drug levels in the maternal serum, cord blood and breast milk of a ustekinumab-treated patient with Crohn's disease","volume":"13","author":"Klenske","year":"2019","journal-title":"J Crohns Colitis"},{"issue":"1","key":"10.1016\/j.ard.2025.02.021_bib0098","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40780-022-00249-8","article-title":"Ustekinumab during pregnancy and lactation: drug levels in maternal serum, cord blood, breast milk, and infant serum","volume":"8","author":"Saito","year":"2022","journal-title":"J Pharm Health Care Sci"},{"issue":"6","key":"10.1016\/j.ard.2025.02.021_bib0099","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.3390\/nu13061810","article-title":"The breast milk immunoglobulinome","volume":"13","author":"Rio-Aige","year":"2021","journal-title":"Nutrients"},{"issue":"11","key":"10.1016\/j.ard.2025.02.021_bib0100","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1007\/s00228-019-02723-z","article-title":"Breast milk concentration of hydroxychloroquine in Chinese lactating women with connective tissue diseases","volume":"75","author":"Peng","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"issue":"14","key":"10.1016\/j.ard.2025.02.021_bib0101","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1177\/0961203318809178","article-title":"Changes in the blood level, efficacy, and safety of tacrolimus in pregnancy and the lactation period in patients with systemic lupus erythematosus","volume":"27","author":"Hiramatsu","year":"2018","journal-title":"Lupus"},{"issue":"9","key":"10.1016\/j.ard.2025.02.021_bib0102","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/jcph.1122","article-title":"Prednisone pharmacokinetics during pregnancy and lactation","volume":"58","author":"Ryu","year":"2018","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.ard.2025.02.021_bib0103","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1177\/1352458517717806","article-title":"Safety of IV pulse methylprednisolone therapy during breastfeeding in patients with multiple sclerosis","volume":"24","author":"Boz","year":"2018","journal-title":"Mult Scler"},{"key":"10.1016\/j.ard.2025.02.021_bib0104","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2020.106118","article-title":"Methylprednisolone concentrations in breast milk and serum of patients with multiple sclerosis treated with IV pulse methylprednisolone","volume":"197","author":"Zengin Karahan","year":"2020","journal-title":"Clin Neurol Neurosurg"},{"issue":"6","key":"10.1016\/j.ard.2025.02.021_bib0105","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1177\/1352458514565414","article-title":"High-dose methylprednisolone for multiple sclerosis during lactation: concentrations in breast milk","volume":"21","author":"Strijbos","year":"2015","journal-title":"Mult Scler"},{"issue":"2","key":"10.1016\/j.ard.2025.02.021_bib0106","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/0890334415570970","article-title":"Transfer of methylprednisolone into breast milk in a mother with multiple sclerosis","volume":"31","author":"Cooper","year":"2015","journal-title":"J Hum Lact"},{"key":"10.1016\/j.ard.2025.02.021_bib0107","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jpba.2015.12.006","article-title":"Determination and quantitation of sildenafil and its major metabolite in the breast milk of a lactating woman","volume":"120","author":"Wollein","year":"2016","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.ard.2025.02.021_bib0108","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.881084","article-title":"Case report: bosentan and sildenafil exposure in human milk\u2014a contribution from the ConcePTION Project","volume":"13","author":"Nauwelaerts","year":"2022","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/j.ard.2025.02.021_bib0109","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/acr.23924","article-title":"Birth outcomes and disease activity during pregnancy in a prospective cohort of women with psoriatic arthritis and ankylosing spondylitis","volume":"72","author":"Smith","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"10.1016\/j.ard.2025.02.021_bib0110","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.cgh.2024.01.019","article-title":"Tofacitinib in pregnancy: assessing pregnancy and infant outcomes, cord blood, and breast milk concentrations","volume":"23","author":"Mitrova","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.ard.2025.02.021_bib0111","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S2468-1253(23)00158-9","article-title":"Tofacitinib concentrations in plasma and breastmilk of a lactating woman with ulcerative colitis","volume":"8","author":"Julsgaard","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.ard.2025.02.021_bib0112","article-title":"Normal infant immunologic assessment and uneventful live rotavirus vaccination despite continuous tofacitinib exposure in utero and during breastfeeding","volume":"6","author":"Ernest-Suarez","year":"2024","journal-title":"Crohns Colitis 360"},{"issue":"3","key":"10.1016\/j.ard.2025.02.021_bib0113","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.kint.2021.05.010","article-title":"Measurement of the passage of mycophenolic acid into breast milk in a patient with lupus nephritis","volume":"100","author":"Huerta","year":"2021","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.ard.2025.02.021_bib0114","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1007\/s40620-023-01672-2","article-title":"Transfer of mycophenolic acid into human milk","volume":"36","author":"Krutsch","year":"2023","journal-title":"J Nephrol"},{"issue":"6","key":"10.1016\/j.ard.2025.02.021_bib0115","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/humupd\/dmaa022","article-title":"The effect of paternal exposure to immunosuppressive drugs on sexual function, reproductive hormones, fertility, pregnancy and offspring outcomes: a systematic review","volume":"26","author":"Perez-Garcia","year":"2020","journal-title":"Hum Reprod Update"},{"issue":"5","key":"10.1016\/j.ard.2025.02.021_bib0116","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.semarthrit.2018.07.011","article-title":"Safety of anti-rheumatic drugs in men trying to conceive: a systematic review and analysis of published evidence","volume":"48","author":"Mouyis","year":"2019","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.ard.2025.02.021_bib0117","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1053\/j.gastro.2021.03.020","article-title":"Paternal exposure to immunosuppressive and\/or biologic agents and birth outcomes in patients with immune-mediated inflammatory diseases","volume":"161","author":"Meserve","year":"2021","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1016\/j.ard.2025.02.021_bib0118","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/annrheumdis-2022-eular.1345","article-title":"OP0131: what is the effect of methotrexate on semen parameters of men diagnosed with immune-mediated diseases? Results of a prospective cohort study (iFAME-MTX)","volume":"81","author":"Perez-Garcia","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.ard.2025.02.021_bib0119","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/ard-2023-224017","article-title":"Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studies","volume":"82","author":"Reinisch","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ard.2025.02.021_bib0120","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.urology.2017.02.032","article-title":"The effect of oral phosphodiesterase-5 inhibitors on sperm parameters: a meta-analysis and systematic review","volume":"105","author":"Tan","year":"2017","journal-title":"Urology"},{"issue":"7","key":"10.1016\/j.ard.2025.02.021_bib0121","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/thoraxjnl-2016-208441","article-title":"Lesson of the month: selective use of cyclophosphamide in pregnancy for severe autoimmune respiratory disease","volume":"71","author":"Nelson-Piercy","year":"2016","journal-title":"Thorax"},{"issue":"4","key":"10.1016\/j.ard.2025.02.021_bib0122","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.ekir.2023.01.006","article-title":"Kidney-limited full-house lupus-like membranous nephropathy and membranoproliferative glomerulonephritis in pregnancy","volume":"8","author":"Orozco-Guill\u00e9n","year":"2023","journal-title":"Kidney Int Rep"},{"issue":"8","key":"10.1016\/j.ard.2025.02.021_bib0123","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/acr.21983","article-title":"Vasculitis Clinical Research Consortium. Pregnancy outcomes among patients with vasculitis","volume":"65","author":"Clowse","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"10.1016\/j.ard.2025.02.021_bib0124","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/FTD.0000000000000769","article-title":"Usage of tacrolimus and mycophenolic acid during conception, pregnancy, and lactation, and its implications for therapeutic drug monitoring: a systematic critical review","volume":"42","author":"Le","year":"2020","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.ard.2025.02.021_bib0125","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.reprotox.2017.04.007","article-title":"Leflunomide\u2014a human teratogen? A still not answered question. An evaluation of the German Embryotox pharmacovigilance database","volume":"71","author":"Weber-Schoendorfer","year":"2017","journal-title":"Reprod Toxicol"},{"issue":"8","key":"10.1016\/j.ard.2025.02.021_bib0126","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1093\/rheumatology\/keaa064","article-title":"Maternal and neonatal outcomes associated with biologic exposure before and during pregnancy in women with inflammatory systemic diseases: a systematic review and meta-analysis of observational studies","volume":"59","author":"Tsao","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.ard.2025.02.021_bib0127","first-page":"9","article-title":"High rate of preterm birth in pregnancies complicated by rheumatoid arthritis","volume":"31","author":"Langen","year":"2014","journal-title":"Am J Perinatol"},{"issue":"4","key":"10.1016\/j.ard.2025.02.021_bib0128","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1365-2796.2010.02239.x","article-title":"Rheumatoid arthritis and birth outcomes: a Danish and Swedish nationwide prevalence study","volume":"268","author":"N\u00f8rgaard","year":"2010","journal-title":"J Intern Med"},{"issue":"11","key":"10.1016\/j.ard.2025.02.021_bib0129","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1002\/art.24914","article-title":"Association of higher rheumatoid arthritis disease activity during pregnancy with lower birth weight: results of a national prospective study","volume":"60","author":"de Man","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.ard.2025.02.021_bib0130","doi-asserted-by":"crossref","first-page":"e913","DOI":"10.1212\/NXI.0000000000000913","article-title":"Anti-CD20 therapies and pregnancy in neuroimmunologic disorders: a cohort study from Germany","volume":"8","author":"K\u00fcmpfel","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"11","key":"10.1016\/j.ard.2025.02.021_bib0131","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1136\/annrheumdis-2018-213004","article-title":"Lymphocyte changes and vaccination response in a child exposed to belimumab during pregnancy","volume":"77","author":"Bitter","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2025.02.021_bib0132","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.reprotox.2003.10.007","article-title":"Pregnancy outcome after first trimester exposure to corticosteroids: a prospective controlled study","volume":"18","author":"Gur","year":"2004","journal-title":"Reprod Toxicol"},{"key":"10.1016\/j.ard.2025.02.021_bib0133","doi-asserted-by":"crossref","first-page":"j895","DOI":"10.1136\/bmj.j895","article-title":"Risk of serious infections associated with use of immunosuppressive agents in pregnant women with autoimmune inflammatory conditions: cohort study","volume":"356","author":"Desai","year":"2017","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.ard.2025.02.021_bib0134","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1093\/rheumatology\/kez405","article-title":"Oral corticosteroid use during pregnancy and risk of preterm birth","volume":"59","author":"Palmsten","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.ard.2025.02.021_bib0135","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jaip.2020.07.047","article-title":"Chambers CD. Oral corticosteroids and risk of preterm birth in the California Medicaid Program","volume":"9","author":"Palmsten","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"8","key":"10.1016\/j.ard.2025.02.021_bib0136","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/acr.24865","article-title":"Differences in the association between oral glucocorticoids and risk of preterm birth by data source: reconciling the results","volume":"74","author":"Palmsten","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"7","key":"10.1016\/j.ard.2025.02.021_bib0137","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1136\/gutjnl-2019-319129","article-title":"Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life","volume":"70","author":"Kanis","year":"2021","journal-title":"Gut"},{"issue":"8","key":"10.1016\/j.ard.2025.02.021_bib0138","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/acr.23730","article-title":"Factors associated with preterm delivery among women with rheumatoid arthritis and women with juvenile idiopathic arthritis","volume":"71","author":"Smith","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"10.1016\/j.ard.2025.02.021_bib0139","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/pds.4410","article-title":"Patterns of prednisone use during pregnancy in women with rheumatoid arthritis: daily and cumulative dose","volume":"27","author":"Palmsten","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.ard.2025.02.021_bib0140","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.reprotox.2021.05.006","article-title":"First trimester naproxen exposure and outcome of pregnancy\u2014a German case series","volume":"103","author":"Hultzsch","year":"2021","journal-title":"Reprod Toxicol"},{"issue":"10","key":"10.1016\/j.ard.2025.02.021_bib0141","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s00228-019-02712-2","article-title":"Risk estimation of fetal adverse effects after short-term second trimester exposure to non-steroidal anti-inflammatory drugs: a literature review","volume":"75","author":"Dathe","year":"2019","journal-title":"Eur J Clin Pharmacol"},{"issue":"18","key":"10.1016\/j.ard.2025.02.021_bib0142","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph191811207","article-title":"Sildenafil during the 2nd and 3rd trimester of pregnancy: trials and tribulations","volume":"19","author":"De Bie","year":"2022","journal-title":"Int J Environ Res Public Health"},{"issue":"10","key":"10.1016\/j.ard.2025.02.021_bib0143","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1111\/bcp.14538","article-title":"Infant drug exposure via breast milk","volume":"88","author":"Verstegen","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.ard.2025.02.021_bib0144","article-title":"Technical report: breastfeeding and the use of human milk","volume":"150","author":"Meek","year":"2022","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.ard.2025.02.021_bib0145","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1093\/ecco-jcc\/jjy198","article-title":"Semen quality and sperm DNA integrity in patients with severe active inflammatory bowel disease and effects of tumour necrosis factor-alpha inhibitors","volume":"13","author":"Grosen","year":"2019","journal-title":"J Crohns Colitis"},{"issue":"12","key":"10.1016\/j.ard.2025.02.021_bib0146","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1136\/annrheumdis-2021-220709","article-title":"Impaired fertility in men diagnosed with inflammatory arthritis: results of a large multicentre study (iFAME-Fertility)","volume":"80","author":"Perez-Garcia","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ard.2025.02.021_bib0147","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.fertnstert.2013.10.048","article-title":"Influence of tumor necrosis factor alpha inhibitors on testicular function and semen in spondyloarthritis patients","volume":"101","author":"Ramonda","year":"2014","journal-title":"Fertil Steril"},{"issue":"8","key":"10.1016\/j.ard.2025.02.021_bib0148","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1136\/ard-2023-224032","article-title":"Is methotrexate safe for men with an immune-mediated inflammatory disease and an active desire to become a father? Results of a prospective cohort study (iFAME-MTX)","volume":"82","author":"Perez-Garcia","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.ard.2025.02.021_bib0149","doi-asserted-by":"crossref","first-page":"e57","DOI":"10.1016\/S1470-2045(20)30582-9","article-title":"Fertility preservation for male patients with childhood, adolescent, and young adult cancer: recommendations from the PanCareLIFE Consortium and the International Late Effects of Childhood Cancer Guideline Harmonization Group","volume":"22","author":"Mulder","year":"2021","journal-title":"Lancet Oncol"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725008143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496725008143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T18:12:20Z","timestamp":1763662340000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496725008143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":149,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0003496725008143"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2025.02.021","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antirheumatic drugs in reproduction, pregnancy, and lactation: a systematic literature review informing the 2024 update of the EULAR recommendations","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2025.02.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}